Paper Title
Evaluating a new marker in patients with chronic obstructive pulmonary disease. The ischemia modified albumin paradox

Chronic Obstructive Pulmonary Disease (COPD) is a complex multisystem disorder characterized by inflammatory obstruction of the small airways as in chronic bronchitis or inflammatory destruction as in emphysema. Smoking is the main etiological factor causing COPD. Tobacco smoke causes oxidative stress and free radical damage which is central to the pathogenesis of COPD. Ischemia Modified Albumin (IMA) is a new and an upcoming biomarker that has shown be an excellent marker to quantify oxidative stress and end organ ischemic damage. The aim of our study is to estimate the levels of IMA in patients with COPD and analyze its clinical implications. The test subjects comprised of 20 patients with clinically diagnosed COPD. The control group had 20 apparently healthy individuals. Serum IMA was estimated by the Albumin Cobalt Binding (ABT) Test and represented in Absorbance Units (ABSU). Serum IMA in COPD patients (0.1054±0.0365) was significantly lower than that of the control group (0.2684±0.1103) with a p value of <0.0001. This shows that patients with COPD have altered ischemic status. While other studies evaluating IMA in pathological states associated with ischemic damage like heart failure and diabetes showed a rise in IMA levels, our study demonstrated that IMA levels were low in COPD. This emphasizes the need to carry out further research with regard to IMA and COPD. Index Terms—Biomarker, Chronic Obstructive Pulmonary Disease, Ischemia Modified Albumin, Oxidative stress.